Junctional Epidermolysis Bullosa: Allelic Heterogeneity and Mutation Stratification for Precision Medicine

Irina Condrat 1,2, Yinghong He 1, Rodica Cosgarea 2 and Cristina Has 1 *

1 Department of Dermatology and Venerology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 2 Department of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

Junctional epidermolysis bullosa (JEB) is a hereditary blistering disease caused by reduced dermal-epidermal adhesion due to deficiencies of one of the proteins, laminin-332, type XVII collagen, integrin α6β4 or integrin α3. Significant progress has been achieved in the development of therapies for EB, such as bone-marrow transplantation, local or systemic injections with fibroblasts or mesenchymal stromal cells, readthrough of premature termination codons, or exon skipping. These were tailored in particular for dystrophic EB, which is caused by type VII collagen deficiency and have not yet reached broad clinical practice. Recently, pioneering combined gene and stem cell therapy was successful in treating one boy with junctional EB. Beside these exclusive approaches, no specific therapy to amend the major clinical features, skin and mucosal blistering and non-healing wounds is available to date. Here we extend the mutational spectrum of junctional EB, provide a stratification of COL17A1 mutations and discuss potential molecular therapeutic approaches.

Keywords: junctional epidermolysis bullosa, collagen XVII, COL17A1, mutation, premature termination codon, therapy

INTRODUCTION

Inherited epidermolysis bullosa (EB) is a group of genetic diseases characterized by skin fragility and is caused by mutations in the genes encoding different proteins with roles in cell adhesion. Junctional EB (JEB) is a subtype of EB in which dermal-epidermal adhesion is reduced, due to deficiencies in one of the proteins laminin-332, type XVII collagen, integrin α6β4 or integrin α3 (1).

Type XVII collagen (also known as ERED, BP180, BPA-2, BPAG2, LAD-1, BA16H23.2) is expressed by basal epidermal keratinocytes and plays an important role in cell-matrix interactions as a transmembrane component of the hemidesmosomes. Structurally, type XVII collagen is a homotrimer, consisting of three collagen alpha-1(XVII) chains, each with a molecular weight of 180-kDa. It is a type II protein, which spans the cell membrane with two domains, an endodomain toward the cytosol and an ectodomain toward the lamina densa of the basement membrane. It links, together with integrin α6β4 and CD151, the inner hemidesmosomal plaque consisting of plectin and BPAG1 to the anchoring filaments buildup of laminin-332 (2). The primary, secondary and tertiary structures, post-translational modifications, as well as interactions and functions of type XVII collagen have been recently extensively reviewed (3, 4).
The main function of type XVII collagen as an adhesion molecule is assured by tight, but dynamic incorporation into hemidesmosomal multiprotein complexes in stratified, pseudostratified and transitional epithelia (e.g., skin, oral mucosa, ocular conjunctiva, epithelial basement membrane of the cornea, upper esophagus, transitional epithelium of the bladder). Besides this role in cell-matrix adhesion, type XVII collagen is responsible for maintenance of follicular stem cells, cell polarity, and migration.

Against this dogma, recent studies provide evidence for the presence of type XVII collagen between the basal keratinocytes, this type being known as the non-hemidesmosomal collagen XVII (4). Non-hemidesmosomal collagen XVII is not a part of the dermal-epidermal adhesion and after its discovery, questions emerged regarding its role. Molecular interactions and cross-talk with focal adhesions and the actin cytoskeleton may be implicated (5, 6). Watanabe and colleagues reported that reduction of non-hemidesmosomal collagen XVII in the interfollicular epidermis is involved in physiological aging, but further work is required in order to decode the exact mechanism (4, 5). Besides these findings, type XVII collagen is also found in the hair follicles stem cells and its proteolytic degradation grounds for age-related hair loss, making it a potential targeted candidate for age-related alopecia, explaining definitive hair loss in patients with JEB (7, 8).

Type XVII collagen is encoded by COL17A1 which spans 52 kb of the genome and is located on the long arm of chromosome 10 (10q24.3). COL17A1 consists of 56 exons and short introns. Mutations in this gene lead to a complete or partial loss-of-function of type XVII collagen in tissues and cause generalized or localized skin blistering, amelogenesis imperfecta, epithelial recurrent erosion dystrophy, alopecia and nail dystrophy (3). Although life expectancy is not reduced, patients with JEB due to COL17A1 pathogenic variants experience extensive trauma-induced blistering resulting in multiple wounds that tend to heal slower with time, excessive caries, diffuse progressive irreversible alopecia, and have impaired quality of life (Figure 1).

Currently, EB research is focused on elucidating the disease mechanisms and development of therapies (9). Experimental therapeutic approaches include ex vivo gene therapy to correct LAMB3 and COL7A1 mutations in epidermal stem cells (10, 11), cell therapies for dystrophic EB, repurposed drugs with anti-inflammatory effects for dystrophic EB and EB simplex and topical agents aiming at improving wound healing. There is an urgent need for new treatments for JEB with COL17A1 mutations for which no experimental therapies are presently available.

Extensive genetic testing and research has provided a comprehensive database (Human Gene Mutation Database® Professional 2018.2) with over 100 distinct mutations encountered in COL17A1, but the database constant development is an ongoing task. The need for such mutational and patients databases is crucial for patients' counseling and prognosis. Development of therapies and selection of patients for clinical trials also depends on their individual mutations.

**METHODS**

The study was conducted according to the Principles of Helsinki and was approved by the Ethics Committee of the University of Freiburg. Written informed consent was obtained from the participants for the publication of the case reports and identifiable images included in this article.

**Mutation Detection**

After informed consent genomic DNA was extracted from EDTA-blood using the Qiagen blood minikit (Qiagen, Hilden Germany). In most cases, mutation analysis was performed by

---

**Abbreviations**: EB, epidermolysis bullosa; JEB, junctional epidermolysis bullosa; PTC, premature termination codon; NMD, nonsense mediated decay.
Cell Culture

Human primary keratinocytes were isolated from the skin of the patients and immortalized with the E6E7 genes as previously described (14). Keratinocyte lines were cultured at 37°C in 5% CO₂ in serum-free medium containing epidermal growth factor and bovine pituitary extract (Invitrogen).

RNA Isolation and RT-PCR

Isolation of total RNA from confluent cell monolayers was performed using the RNeasy Plus Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. One Microgram of isolated RNA was used for cDNA synthesis with the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Wilmington, USA) in a volume of 100 µl.

RT-PCR was then performed with 5 µl of the cDNA in a 50 µl mix containing 10x Puffer, nucleoside diphosphatase (dNTP), Taq DNA Polymerase (Sigma) and primers. Primers for COL17A1 cDNA were F: TACCATGTACGTGTCAGGCC and R: TGATGCTGGACCACACACATTG. The annealing temperature was calculated with UCSC in-silico PCR (https://genome.ucsc.edu/cgi-bin/hgPcr).

Immunofluorescence Staining of Skin Sections

Biopsy technique, tissue processions, antigen-antibody interaction, and afterwards visualization were previously described (15).

Protein Isolation and Immunoblotting

For protein extraction, cells were lysed on ice for 20 min in lysis buffer, proteinase inhibitors and phosphatase inhibitors and centrifuged for 20 min at 14,000 rpm. Extracts were subsequently heated to 95°C for 5 min. Bradford assay (BioRad) was used to determine the protein concentration. For collagen XVII immunodetection (case 61), 35 µg protein was run on a 8% SDS Page for 1.5 h and transferred to a nitrocellulose membrane at 300 mA for 1.5 h. For detection, collagen XVII-specific antibodies were used: NC16A, against epitope within the NC16A region, at a dilution of 1:1000 (16).

RESULTS

The results of the genetic and molecular analysis of the cohort are described below. Also, novel mutations, genotype-phenotype correlations, and immunofluorescence mapping are reported in Table 1.

Novel COL17A1 Mutations and Genotype-Phenotype Correlations

This study contributes to the COL17A1 mutational database with 9 mutations that, to the best of our knowledge, have not been reported before (Table 1, Figure 2). These include two nonsense mutations c.1750C>T, p.R584∗ and c.4153C>T, p.Q1385∗, five frameshift mutations, one mutation of the translation initiation codon, and one splice site mutation. Several of these cases demonstrated interesting genotype-phenotype correlations or clinical course of the disease and will be highlighted here.

Case 61 was a female patient suffering from mild skin blistering since birth. Epidermolysis bullosa simplex was suspected and several candidate genes analyzed, but no mutations were found. Clinically, skin blisters and erosions were present on the face, upper posterior thorax, and lower limbs (Figure 3). As the girl grew older, nails became dystrophic and were progressively lost, suggesting the diagnosis of JEB. She was found to be compound heterozygous for the COL17A1 mutations c.1750C>T, p.R584∗ and c.3509-1G>C. To the best of our knowledge both mutations were previously unreported. The mutation c.3509-1G>C is located in intron 49 of COL17A1 and alters the conserved acceptor splice site. RT-PCR and sequencing of the RNA extracted from keratinocytes of the patient revealed that an alternative splice site was used, 33 nucleotides downstream in the middle of exon 50, thus restoring the reading frame and allowing the synthesis of an eleven amino acids shorter truncated polypeptide. Intriguingly, in immunofluorescence mapping, the immunoreactivity for collagen XVII with the commercial monoclonal antibody NC16A3 (Abcam) was comparable to the control skin (Figure 3B). The polyclonal sera NC16A (17) demonstrated reduced immunoreactivity in the skin of the patient and a decreased amount of collagen XVII in lysates from patient’s keratinocytes as compared to the controls (Figure 3B), explaining the mild phenotype.

Case 66 was a 22-year-old male who presented with acral blistering that had started at the age of 16 and was induced by sport activities. Additionally, he displayed nail dystrophy (Figures 1A–C). Immunofluorescence microscopy demonstrated a broadened staining pattern of type XVII collagen and no skin split. Clinical exome sequencing demonstrated that he was compound heterozygous for the COL17A1 mutations c.3908G>A, and the frame shift deletion c.4100..4101delTT, p.F1367Cfs8, that truncates the last 130 amino acids in the C-terminus of the α1(XVII)-chain.

The severe clinical picture of generalized intermediate JEB is illustrated in case 68 from our cohort, a 45-year-old male, compound heterozygous for the previously unpublished mutation in the translation initiation codon, c.2T>A, p.?, and the also novel frame-shift deletion c.3164delT, p.F1055Fs*11. Generalized blistering resulted in multiple chronic non-healing wounds at sites of permanent trauma (Figures 1D,E); on such a wound on the lower left leg, he developed a squamous cell carcinoma at the age of 44 (Figure 1F). Although initially the histological aspect was that of a verrucous carcinoma, recurrence occurred rapidly with local invasion, necessitating amputation. This is the only patient of this cohort who developed squamous cell carcinoma during the observation period. Squamous cell carcinoma has been reported in JEB patients from The Netherlands (18), but the precise risk for developing this complication in JEB remains unknown.
Stratification of COL17A1 Mutations

Stratified medicine, and in particular stratification of mutations, focuses on establishing a therapeutic approach tailored to the specific needs of a patient. Therefore, determining the most prevalent mutations and addressing their consequences is a practical and feasible concept, with previous work in cystic fibrosis supporting this aim (19). Currently, no international database of patients with JEB and COL17A1 mutations is available, although many countries have established registries with clinical, molecular and follow up data for EB patients. Over 100 distinct COL17A1 mutations have been reported in the literature (HGMD professional as of 1/15/2018) including 24 nonsense mutations, 14 missense mutations, 24 splicing mutations, 27 small deletions, 20 small insertions, one small indel, one gross deletion, and one gross insertion. Even though COL17A1 is the only gene involved, phenotypes may differ in severity, so that mutations leading to complete loss of type XVII collagen will result in a more severe phenotype as compared to mutations that allow some degree of protein synthesis and function.

TABLE 1 | Mutational analysis, immunofluorescence mapping and genotype-phenotype correlations of the patients previously unpublished.

| Case | Mutations c.DNA level | Mutation Protein level | Immunofluorescence | Clinical phenotype (age) |
|------|-----------------------|-----------------------|--------------------|-------------------------|
| 44   | c.4153C>T             | p.Q1385*              | Not available      | Not available           |
| 45   | c.2861delG            | p.G954Afs*112         | Not available      | Not available           |
| 49   | c.2062C>T             | p.R688*               | Negative staining for collagen XVII | Severely affected with generalized blistering, nail dystrophy (age 1) |
| 50   | c.2407G>T             | p.G803*               | Reduced immunoreactivity for collagen XVII | Multiple blisters and erosions, nail loss, dental abnormalities (age 3) |
| 51   | c.[3487G>T;4319dup]   | p.[E1163*;G1441Wfs*14]| Reduced immunoreactivity for collagen XVII | Mildly affected, nail dystrophy (age 1) |
| 52   | c.2237del             | p.G746Afs*53         | Reduced immunoreactivity for collagen XVII, almost negative | Severely affected, extensive blisters and erosion, nail loss (1 week old) |
| 58   | c.[1418_419delAG      | p.S140*               | Reduced immunoreactivity for collagen XVII, almost negative | Not available |
| 59   | c.[2237delG;3198C>T]  | p.[G746Afs*53;S1066S]| Strongly reduced immunoreactivity for collagen XVII at the blister roof | Mildly affected |
| 60   | c.2062C>T             | R688*                 | Negative staining for collagen XVII | Not available |
| 61   | c.[1750C>T;3509-1G>C] | p.[R584*;?]           | Reduced immunoreactivity for collagen XVII at blister floor (Figure 3) | Mildly affected, nail dystrophy and loss (age 2) (Figure 3) |
| 62   | c.2282_2283delGG      | p.G761Dfs*40         | Reduced immunoreactivity for collagen XVII, almost negative | Not available |
| 64   | c.[779delC;3569dupG]  | p.[P260Qfs*32;N1191Qfs*51]| Reduced immunoreactivity for collagen XVII at blister roof | Skin blisters, alopecia, nail loss |
| 65   | c.2062C>T             | p.R688*               | Negative staining for collagen XVII | Falcid serous and hemorrhagic blisters, alopecia, poikilodermatous hypopigmented areas, mucosal involvement, generalized enamel defects |
| 66   | c.[3908G>A;4100_4101delTT] | p.[R1303Q;F1367Cfs*8] | Collagen XVII is present at blister roof | Mildly affected (see Figure 1) |
| 68   | c.[2T>A;3164delT]     | p.[?;F1055Sfs*11]    | Not available      | Severely affected (see Figure 1) and squamous cell carcinoma |

*if only one mutation mentioned, then homozygous.

Mutations in bold have not been reported before.
In the past 15 years we have systematically performed molecular diagnostics for EB employing immunofluorescence mapping and mutation detection (13, 15). Altogether, we identified 68 patients with JEB with COL17A1 mutations, with a mean of about 5 new cases per year.

Fifty distinct COL17A1 mutations were identified (Table 2). Evaluation and stratification of these mutations was performed based on the number of allelic encounters and mutation type (Figure 2). As shown in Figure 2, most mutations are unique, occurring in single cases / families and only few are recurrent. Approximately 33% of COL17A1 mutant alleles are nonsense mutations, and another 33% are frame shift mutations leading to formation of premature termination codons (PTC). Splice site mutations account for 10% of mutant alleles.

In this cohort, the most frequent recurrent mutation was c.3908G > A, p.R1303Q detected in 16.17% of cases and 14.70% of the mutant alleles (in 9 patients in a homozygous state and in 2 patients in heterozygous manner), respectively. This missense mutation changes the amino acid arginine with glutamine and is located in the fourth non-collagenous domain (NC4) of the α1(XVII)-chain, which is part of the putative laminin-332 binding region in type XVII collagen (20). Secondary protein structure analysis and predicted changes in the structural integrity within this binding region suggested that these modifications result in abnormal laminin-332 binding (21). This mutation also appears to hamper the physiological C-terminal cleavage of type XVII collagen. Consequently, non-cleaved type XVII collagen ectodomain remnants induce the aberrant deposition of laminin-332 in the extracellular matrix (12, 22). Clinically, p.R1303Q is associated with a mild, Kindler-syndrome-like phenotype, manifesting with late onset skin blistering, progressive skin atrophy and sclerosis, loss of dermatoglyphics, scarring, and nail anomalies. Typically, type XVII collagen is deposited at the dermal-epidermal junction in a broad irregular pattern (13, 16).

Second most common mutation was c.2407G > T, representing 6.61% of the mutant alleles in 10.29% of cases (in 5 patients in a heterozygous state and in 2 homozygous patients). This mutation located in exon 34, where it converts a glycine residue to a premature termination codon (PTC), p.G803*, was also frequent in patients with Austrian (18) and Finish background (23). With the same allele frequency there was also c. 3676C > T, found in 11.76% of patients. It also translates into a PTC, p.R1226*.

Next, we found c.2062C > T, p.R688*, c.2861delG, p.G954Af*112 and 418_419delAG, p.S140* to represent 4.41% of the mutant alleles in 4.31% of our patients. All these null-mutations lead to absence of type XVII collagen and generalized intermediate JEB (previously known as generalized atrophic benign epidermolysis bullosa (GABEB) and...
DISCUSSIONS

Consequences of COL17A1 Mutations and Potential Therapeutic Strategies

Potential therapeutic strategies emerge from analysis of the mutations, their consequences and from the resulting phenotypes (Table 2). Patients with acral or late onset JEB, like our cases 61 and 66, have limited disease burden and can be treated symptomatically. In contrast, severely affected patients, like our case 68 require effective therapeutic strategies for their chronic wounds. There is also no existing treatment for other disease manifestations, such as: (i) hair loss, which is definitive; (ii) nail dystrophy or loss, which are regarded as cosmetic problems; (iii) amelogenesis imperfecta leading to increased caries and premature destruction of teeth, which require careful and sustained dental care and treatment. The analysis of genotype-phenotype correlations in patients the JEB suggests that 12–25% of the normal type XVII collagen levels are sufficient to provide a certain degree of skin stability and consequently ameliorate the phenotype (3).

Taking into account the large number of COL17A1 PTC-mutations, therapies to restore the mutant gene seem to be appropriate in this EB subtype. In our study 33% of mutations are nonsense mutations. These relatively high figures render the thoroughfare for an efficient therapeutic approach directed against these particular types of mutations. Ex-vivo gene therapy, where the defective gene is corrected, transduced in cells and later grafted to the patient is highly complex and expensive. As an alternative approach, RNA trans-splicing was developed and showed expression of the replaced exon 52 in up to 61% assayed cells in vitro (26).

Revertant mosaicism is frequent in patients with JEB-COL17A1 (18), but GMP-cultivation and expansion of revertant epidermal stem cells is not yet broadly available. Because type XVII is solely synthetized by keratinocytes and must be correctly assembled as a transmembrane protein in a supramolecular complex, fibroblast / mesenchymal stem cell therapies and protein therapy are not feasible.

Type XVII collagen has a modular collagenous structure, and COL17A1 has 54 out of 56 exons in-frame, except of the first and last. In-frame truncations seem to be tolerated, and account for the presence of molecules which are stable and partially functional, such in our case 61 and in other cases reported in the literature (27, 28). Thus, antisense-mediated skipping of exons with PTCs might also be an alternative strategy for COL17A1 mutations (29).

Nevertheless, drug-based therapeutic strategies that aim to modify either the synthesis of protein by inducing readthrough or the mechanisms that lay the ground for RNA translation might be easier available. Suppression of stop codons and enabling readthrough in translation can be effective for several genetic disorders, including EB (24, 27, 30, 31).

Readthrough therapy modifies the response of the translational ribosome to nonsense mutations, by allowing a near-cognate aminoacyl tRNA to step into the spot on the stop codon and thus proceeding toward protein synthesis and allowing a functional protein to be produced. In order to restore
| COL17A1 mutations cDNA | Location | Mutation protein | Proposed treatment | Comment |
|------------------------|----------|------------------|--------------------|---------|
| 2T>A                   | 2        | ?                | Gene therapy       |         |
| 2T>C                   | 2        | ?                | Gene therapy       |         |
| 53_1224del             | 3        | ?                | Gene therapy       |         |
| 418_419delAG           | 8        | S140*            | Readthrough        |         |
| 433C>T                 | 8        | R145*            | Readthrough        |         |
| 460C>T                 | 8        | R154*            | Readthrough        |         |
| 779del                 | 11       | P260Qfs*32       | Gene therapy       |         |
| 1141+5G>A              | IVS14    | Residual expression of full-length collagen XVII due to leaky splice site | Symptom relieving therapies | Moderate disease severity |
| 1392G>A                | 17       | W484*            | Readthrough        |         |
| 1480_1482dup           | 18       | K494dup          | Symptom relieving therapies | Moderate disease severity |
| 1601_1602insG          | 18       | S534Efs*10       | Exon 18 in frame skipping |         |
| 1616G>A                | 18       | G539E            | Symptom relieving therapies | Moderate disease severity |
| 1744-2A>C              | IVS20    | In frame skipping of exons 21 and 22 or partial skipping of exon 21 leading to residual expression of collagen XVII | Symptom relieving therapies | Moderate disease severity |
| 1750C>T                | 21       | R584*            | Readthrough        |         |
| 1826G>A                | 22       | G609D            | Symptom relieving therapies | Moderate disease severity |
| 1834G>A                | 22       | G612R            | Symptom relieving therapies | Moderate disease severity |
| 1861G>A                | 23       | G621S            | Symptom relieving therapies | Moderate disease severity |
| 1898G>A                | 23       | G633D            | Symptom relieving therapies | Moderate disease severity |
| 2003-1G>C              | IVS24    | ?                | Gene therapy       |         |
| 2062C>T                | 26       | R688*            | Readthrough        |         |
| 2237delG               | 30       | G746Afs*53       | Exon 30 in frame skipping |         |
| 2282_2283delGG         | 31       | G761Dfs*40       | Exon 31 in frameskipping |         |
| 2336-2A>G              | IVS31    | In frame skipping of exon 32 leading to expression of truncated protein | Symptom relieving therapies | Moderate disease severity |
| 2338C>T                | 33       | R795*            | Readthrough        |         |
| 2407G>T                | 34       | G803*            | Readthrough        |         |
| 2561_2565delAATTG      | 37       | N854Tfs*109      | Exon 37 in frame skipping |         |
| 2561_2562delTT         | 37       | N854fs*110       | Exon 37 in frame skipping |         |
| 2564T>G                | 37       | L855*            | Readthrough        |         |
| 2723dup                | 40       | G909Rfs*56       | Exon 40 in frame skipping |         |
| 2861delG               | 43       | G954Afs*112      | Exon 43 in frame skipping |         |
| 2993dupC               | 44       | G999Wfs*22       | Exon 44 in frame skipping |         |
| 3046C>T                | 45       | Q1016*           | Readthrough        |         |
| 3164delT               | 46       | F1055Sfs*11      | Exon 46 in frame skipping |         |
| 3198C>T                | 46       | Residual expression of full-length collagen XVII due to leaky splice site | Symptom relieving therapies | Moderate disease severity |
| 3487G>T                | 49       | E1163*           | Readthrough        |         |
| 3505C>T                | 49       | R1169*           | Readthrough        |         |
| 3509-1G>C              | IVS49    | In frame skipping of part of exon 50 leading to truncated protein expression | Symptom relieving therapies | Moderate disease severity |
| 3548delC               | 50       | P1183Rfs*68      | Exon 50 in frame skipping |         |
| 3569dupG               | 50       | N1191Qfs*51      | Exon 50 in frame skipping |         |
| 3676C>T                | 51       | R1226*           | Readthrough        |         |
| 3766+1G>C              | IVS51    | Out of frame and absence of collagen XVII | Gene therapy |         |
| 3766+5G>A              | IVS51    | Absence of collagen XVII | Gene therapy |         |
| 3800dupC               | 52       | G1268Rfs*25      | Exon 52 in frame skipping |         |
| 3865dupA               | 52       | S1289Kfs*4       | Exon 52 in frame skipping |         |

(Continued)
### TABLE 2 | Continued

| COL17A1 mutations cDNA | Location | Mutation protein | Proposed treatment | Comment |
|------------------------|----------|------------------|--------------------|---------|
| 3908G>A                | 52       | R1303Q           | Symptom relieving therapies | Late onset and moderate disease severity |
| 4153C>T                | 52       | Q1385*           | Readthrough         |         |
| 4100_4101delTT         | 52       | F1367Cfs*8       | Exon 52 in frame skipping |         |
| 4156+1G>A              | IVS52    | In frame skipping of exon 52 | Symptom relieving therapies | Moderate disease severity |
| 4305_4308dupCATT       | 54       | Q1437Hfs*19      | Symptom relieving therapies | Moderate disease severity |
| 4319dupC               | 54       | G1441Wfs*14      | Symptom relieving therapies | Moderate disease severity |

*stands for a premature termination codon.

the function of nonsense mutations carrying genes several compounds have been identified in the last decades. The PTCs are normally recognized by a mechanism called nonsense-mediated mRNA decay (NMD), which tries to eliminate them in order to reduce errors in the expression of a particular gene. NMD efficiency can influence the response of readthrough by several factors (32). Particularly, when some key factors in NMD pathway are inhibited, such as ATP dependent RNA helicase upframeshift 1 (UPF1) and upframeshift 2 (UPF2), a better function of the gene implicated in the pathology of cystic fibrosis was noticed (32). On the contrary, in recessive dystrophic epidermolysis bullosa, it has been shown that a better response to readthrough was associated with an increase in the factor UPF1 in all cells treated, results which support that the more stable this UPF1 factor is, the more inhibited NMD pathway is (33). Another factor that can be limiting in the response of readthrough could be the PTC bearing transcripts of patients. These may vary among individuals and could be beneficial to assess before treatment (32).

### CONCLUSIONS

We report here nine previously unpublished mutations, which will enhance the already established database with COL17A1 mutations. The additionally reported genotype-phenotype correlations will help in diagnosis and genetic counseling, thus providing advantage in the clinical setting. The stratification of the mutations and their consequences should also provide insights for mutation analysis strategies and potential therapies.

As far as therapeutic strategies are regarded for COL17A1 PTC-mutations, readthrough compounds and exon skipping-approaches seem to be reliable and aim at increasing stability of the skin, wound healing and improving the quality of life. Progress still needs to be made for the other cutting-edge therapeutic possibilities.

### AUTHOR CONTRIBUTIONS

CH has molecularly characterized the cohort of patients and has written the final version of the manuscript. IC has analyzed the data, performed the molecular analyses in patient 61, the characterization of the cell lines and has drafted the manuscript and figures. YH has analyzed data. RC has contributed with the phenotypes analysis. All authors have read and corrected the manuscript.

### FUNDING

The work of CH is funded by Debra International and by BMBF (E-Rare-ERA-NET MuTaEB 01GM1805), and IC has received a Research Fellowship RF 2017-21 from EADV.

### ACKNOWLEDGMENTS

We thank Dr. Julie Christiansen for sending samples and providing clinical pictures of patient 61. We thank Prof. Jürgen Kohlhase and his team for the collaboration. We thank all patients and their families and our physician colleagues. The excellent technical assistance of Juna Leppert, Vera Morand, Gabriele Grüninger, Käthe Thoma, and Ioannis Athanasiou is acknowledged. We thank also Kirstyn Crossley for proofing the manuscript language-wise. We thank all our clinician colleagues and the EB center Freiburg.

### REFERENCES

1. Fine J-D, Bruckner-Tuderman L, Eady RAJ, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. *J Am Acad Dermatol.* (2014) 70:1103–26. doi: 10.1016/j.jaad.2014.01.903
2. Walko G, Castaño M, Wiche G. Molecular architecture and function of the hemidesmosome. *Cell Tissue Res.* (2015) 360:529–44. doi: 10.1007/s00441-015-2216-6
3. Has C, Nystöm A, Saedian AH, Bruckner-Tuderman L, Uitto J. Epidermolysis bullosa: Molecular pathology of connective tissue components in the cutaneous basement membrane zone. *Matrix Biol.* (2018) 71–72:313–29. doi: 10.1016/j.matbio.2018.04.001
4. Natsuga K, Watanabe M, Nishie W, Shimizu H. Life before and beyond blistering: the role of collagen XVII in epidermal physiology. *Exp Dermatol.* (2018) doi: 10.1111/exd.13550. [Epub ahead of print].
5. Watanabe M, Natsuga K, Nishie W, Kobayashi Y, Donati G, Suzuki S, et al. Type XVII collagen coordinates proliferation in the interfollicular epidermis. *elfe* (2017) 6:e26653. doi: 10.7534/elfe.26653

6. Hiroyasu S, Coburn ZT, Jones JCR. A hemidesmosomal protein regulates actin dynamics and traction forces in motile keratinocytes. *FASEB J* (2016) 30:2298–310. doi: 10.1096/fj.20150016OR

7. Matsumura H, Mohri Y, Binh NT, Morinaga H, Fukuda M, Ito M, et al. Hair follicle aging is driven by transdermal elimination of stem cells via COL17A1 proteolysis. *Science* (2016) 351:aad4395. doi: 10.1126/science.aad4395

8. Tamiru T, Tadokoro Y, Inomata K, Binh NT, Nishie W, Yamazaki S, et al. Hair follicle stem cells provide a functional niche for melanocyte stem cells. *Cell Stem Cell* (2011) 8:177–87. doi: 10.1016/j.stem.2010.11.029

9. Uitto J, McGrath JA, Rodeck U, Bruckner-Tuderman L, Robinson EC. Progress in epidermolysis bullosa research: toward treatment and cure. *J Invest Dermatol.* (2010) 130:1778–84. doi: 10.1038/jid.2010.90

10. Hirsch T, Rothoef T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. *Nature* (2017) 551:327–32. doi: 10.1038/nature24487

11. Siprasvili Z, Nguyen NT, Gorell ES, Loutit K, Khoo P, Furukawa LK, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. *JAMA* (2016) 316:1808–17. doi: 10.1001/jama.2016.15388

12. Kroeger J, Hoppe E, Galiger C, Has C, Franzke C-W. Amino acid substitution in the C-terminal domain of collagen XVII reduces laminin-332 interaction causing mild skin fragility with atrophic scarring. *Matrix Biol J Int Soc Matrix Biol.* (2018). doi: 10.1016/j.matbio.2018.10.003

13. Has C, Küsel J, Reimer A, Hoffmann J, Schauer F, Zimmer A, et al. The position of targeted next-generation sequencing in epidermolysis bullosa diagnosis. *Acta Derm Venereol.* (2018) 98:437–40. doi: 10.2340/00015 553-2863

14. Maier K, He Y, Esser PR, Thiene K, Sarca D, Kohlhase J, et al. Novel single amino acid deletion in kindlin-1 results in partial protein degradation which can be rescued by chaperone treatment. *J Invest Dermatol.* (2016) 136:920–9. doi: 10.1016/j.jid.2015.12.039

15. Has C, He Y. Research techniques made simple: immunofluorescence antigen mapping in epidermolysis bullosa. *J Invest Dermatol.* (2016) 136:e65–71. doi: 10.1016/j.jid.2016.05.093

16. Scähcke H, Schumann H, Hammami-Hauasli N, Raghunath M, Bruckner-Tuderman L. Two forms of collagen XVII in keratinocytes. A full-length transmembrane protein and a soluble ectodomain. *J Biol Chem.* (1998) 273:25937–43. doi: 10.1074/jbc.273.40.25937

17. Yuen WY, Pas HH, Sinke RJ, Jonkman MF. Junctional epidermolysis bullosa of late onset explained by mutations in COL17A1. *Br J Dermatol.* (2011) 164:1280–4. doi: 10.1111/j.1365-2133.2011.09359.x

18. Darling TN, McGrath JA, Yue C, Gatalica B, Hametner R, Bauer JW, et al. Premature termination codons are present on both alleles of the bullos pemphigoid antigen 2/type XVII collagen gene in five Austrian families with generalized atrophic benign epidermolysis bullosa. *J Invest Dermatol.* (1997) 108:463–8. doi: 10.1111/1523-1747.ep12289718

19. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. *Hum Mutat.* (2002) 19:575–606. doi: 10.1002/humu.10041

20. Tanasen K, Tunggal L, Chometon G, Bruckner-Tuderman L, Aumaillé M. Keratinocytes from patients lacking collagen XVII display a migratory phenotype. *Am J Pathol.* (2004) 164:2027–38. doi: 10.1016/S0002-9440(04)03672-5

21. Has C, Kiritsi D, Mellerio JE, Franze C-W, Wedgeworth E, Tancheva-Poor I, et al. The missense mutation p.R1303Q in type XVII collagen underlies junctional epidermolysis bullosa resembling Kindler syndrome. *J Invest Dermatol.* (2014) 134:845–9. doi: 10.1038/jid.2013.367

22. Nishimura M, Nishie W, Shirafuji Y, Shinkuma S, Natsuga N, Nakamura H, et al. Extracellular cleavage of collagen XVII is essential for correct cutaneous basement membrane formation. *Hum Mol Genet.* (2016) 25:328–39. doi: 10.1093/hmg/ddv478

23. Gatalica B, Pulkkinen L, Li K, Kuokkanen K, Rynänen M, McGrath JA, et al. Cloning of the human type XVII collagen (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa. *Am J Hum Genet.* (1997) 60:352–65.

24. Pasmooj AMG, Pas HH, Jansen GHL, Lemmink HH, Jonkman MF. Localization and generalized forms of blistering in junctional epidermolysis bullosa due to COL17A1 mutations in the Newfoundland. *Br J Dermatol.* (2007) 156:861–70. doi: 10.1111/j.1365-2133.2006.07730.x

25. McGrath JA, Gatalica B, Christiano AM, Li K, Owaribe K, McMullan JR, et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. *Nat Genet.* (1995) 11:83–6. doi: 10.1038/ng0995-83

26. Koller U, Wally V, Mitchell LG, Klausggezer A, Mauerum EA, Mayr E, et al. A novel screening system improves genetic correction by internal exon replacement. *Nucleic Acids Res.* (2011) 39:e1308. doi: 10.1093/nar/gkr465

27. Yancey KB, Hintner H. Non-herlitz junctional epidermolysis bullosa. *Dermatol Clin.* (2010) 28:67–77. doi: 10.1016/j.dcl.2009.10.008

28. Hintner H, Wolff K. Generalized atrophic benign epidermolysis bullosa. *Arch Dermatol.* (1982) 118:375–84. doi: 10.1001/archderm.1982.0165018

29. Lincoln V, Cogan J, Hou Y, Hirsch M, Hao M, Alexeev V, et al. Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa. *Proc Natl Acad Sci USA.* (2018) 115:E6336–45. doi: 10.1073/pnas.1803154115

30. Huber M, Floeth M, Borradori L, Scähcke H, Rugg EL, Lane ER, et al. Deletion of the cytoplasmatic domain of BP180/collagen XVII causes a phenotype with predominant features of epidermolysis bullosa simplex. *J Invest Dermatol.* (2002) 118:185–92. doi: 10.1046/j.0022-202x.2001.0617.x

31. Bruckner-Tuderman L, Has C. Disorders of the cutaneous basement membrane zone—the paradigm of epidermolysis bullosa. *Matrix Biol J Int Soc Matrix Biol.* (2014) 33:29–34. doi: 10.1016/j.matbio.2013.07.007

32. Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. *Trends Genet TIG* (2008) 24:552–63. doi: 10.1016/j.tig.2008.08.010

33. Kurosaki T, Li W, Hoque M, Popp MW-L, Ermolenko DN, Tian B, et al. Hair follicle aging is driven by transepidermal elimination of actin dynamics and traction forces in motile keratinocytes. *Cell Stem Cell* (2018) 6:e26635. doi: 10.7554/eLife.26635

34. Aumailley M. Keratinocytes from patients lacking collagen XVII display a migratory phenotype. *J Invest Dermatol.* (2010) 28:67–77. doi: 10.1016/j.jid.2009.10.008

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.